BRIEF-Antares Pharma Says FDA Accepts Resubmission To CRL For Xyosted NDA By: Reuters: Company News April 05, 2018 at 08:24 AM EDT * ANNOUNCED FDA ACKNOWLEDGED RECEIPT OF RESUBMISSION TO CRL RECEIVED IN CONNECTION WITH XYOSTED NEW DRUG APPLICATION Read More >> Related Stocks: Antares Pharma